고리성형술용 링 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the annuloplasty rings market is expected to grow from USD 1.38 billion in 2025 to USD 1.49 billion in 2026 and is forecasted to reach USD 2.31 billion by 2031 at 9.21% CAGR over 2026-2031.

This report is Segmented by Product Type (Saddle Shaped Annuloplasty Rings, Flat Shaped Annuloplasty Rings), Material (Polyester Fabric-Covered Rings, and More), Application (Mitral Valve Repair, Tricuspid Valve Repair, and More), End-User (Hospitals, Cardiac Surgery Centers, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Annuloplasty Rings Market Trends and Insights

Rising Global Burden of Valvular Heart Disease

Valvular heart disease is becoming a larger part of the global cardiovascular burden, and that shift is directly supporting the annuloplasty rings market. Global non-rheumatic valvular heart disease incidence and the age-standardized incidence rate is projected to reach 20.28 per 100,000 people by 2035. The burden is not evenly distributed, because high Socio-demographic Index regions recorded incidence of 56.45 per 100,000, which is far above the global average and aligns with the regions that already account for much of the annuloplasty rings market. Surgical repair demand follows this pattern closely because mitral and tricuspid regurgitation with annular dilation remain the main settings for ring implantation. That combination of epidemiology and earlier diagnosis gives the annuloplasty rings market a broader procedure base than demographic aging alone would suggest.

Aging Cardiovascular Patient Pool Requiring Valve Repair

The aging patient pool remains a core long-range support for the annuloplasty rings market. In patients aged 55 years and older, the age-standardized prevalence rate reached 1,876.01 per 100,000, which was close to 5x the global average and reflects the strong age link in degenerative valve disease. This matters most in North America and Europe, where the over-65 population continues to grow and where established surgical systems can convert diagnosis into procedure volume more efficiently. A notable pattern is the increase in patients in their 60s who remain good repair candidates and who are often steered toward ring-based repair because it avoids the long-term issues tied to anticoagulation and structural valve deterioration. In Asia-Pacific, the size of the older population creates a large latent pool that will translate into higher procedure volumes as tertiary cardiac infrastructure expands. As that access improves, the annuloplasty rings market should benefit not only from more elderly patients, but also from better identification of patients who can still tolerate definitive repair.

High Procedure and Device Cost in Elective Valve Repair

High cost remains a meaningful volume restraint for the annuloplasty rings market, especially where elective cardiac surgery competes with limited health budgets. The 2025 Accra Declaration stated that imported surgical consumables remain a major challenge for sustainable cardiac surgery in Africa, despite significant unmet clinical need. The ring itself is only one part of total treatment cost, because cardiopulmonary bypass consumables, perfusion support, anesthesia, and intensive care recovery all add to the final bill. That makes elective valve repair difficult to scale in lower-middle-income settings and can also lead to deferrals when hospitals or payers face cost pressure in developed systems. Manufacturers are trying to reduce some of this friction through pricing flexibility and service support, but the gap between procedure economics and payer capacity is still limiting how far the annuloplasty rings market can reach in cost-sensitive regions. Unless that gap narrows, growth will continue to depend heavily on wealthier systems and premium private networks.

Other drivers and restraints analyzed in the detailed report include:

1. Preference for Valve Repair Over Replacement in Clinical Guidelines
2. Expanding Adoption of Minimally Invasive and Robotic Cardiac Surgery
3. Limited Specialist Access in Low-Resource Cardiac Centers

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Saddle-shaped rings held 53.26% of the annuloplasty rings market share in 2025, making them the largest product category. Their lead comes from long-standing clinical use and from their ability to preserve the native non-planar geometry of the mitral annulus. This geometry helps lower leaflet stress during systole and can reduce the risk of residual regurgitation in appropriately selected repairs. The MANTRA sub-study around the Memo 4D semi-rigid saddle ring showed favorable early hemodynamic outcomes across more than 165 patients treated in 17 international centers, with 91.7% of patients reporting none, trace, or mild mitral regurgitation at 30 days. That clinical base keeps saddle configurations firmly established in the annuloplasty rings market, especially in mitral programs that prioritize durable geometry restoration.

Flat-shaped rings are projected to be the fastest-growing product type in the annuloplasty rings market at a 9.74% CAGR from 2026 to 2031. Their lower profile fits well with thoracoscopic and robotic workflows that depend on smaller access ports and more controlled device handling. As robotic programs expand, product design in the annuloplasty rings industry is likely to favor flatter and more adaptable ring architectures that work more easily with image-guided workflows.

Polyester fabric-covered rings accounted for 42.34% of revenue in 2025, which kept them in the lead across the annuloplasty rings market. Their position reflects a long clinical track record, familiar suturing behavior, and consistent use across rigid and semi-rigid designs. A 2026 retrospective study that reviewed 153 consecutive mitral valve repair patients found that semi-rigid rings, which commonly use polyester sewing platforms, were associated with 2.0% mortality and 95.9% good or moderate repair on follow-up echocardiography. Polyester also remains the preferred outer sewing substrate because it supports controlled tissue ingrowth and is already well understood in implant testing.

Titanium core rings are projected to expand at a 10.13% CAGR through 2031, which makes them the fastest-growing material segment in the annuloplasty rings market. Surgeons are increasingly drawn to the strength-to-weight ratio of metallic core designs, along with MRI compatibility and stronger imaging visibility during follow-up or complex procedures. Nitinol-based concepts are receiving added attention because their shape-memory behavior can allow more dynamic annular remodeling than static polymer or rigid metal formats. As imaging, robotic delivery, and tricuspid repair all gain traction, the annuloplasty rings industry is giving more attention to material systems that improve both procedural handling and long-term structural behavior.

Complete Report Scope:

• By Product Type
  • Saddle Shaped Annuloplasty Rings
  • Flat Shaped Annuloplasty Rings
• By Material
  • Polyester Fabric-Covered Rings
  • Titanium Core Rings
  • Nitinol-Based Rings
  • Other Materials
• By Application
  • Mitral Valve Repair
  • Tricuspid Valve Repair
  • Aortic Valve Repair
  • Pulmonary Valve Repair
  • Combined Valve Repair
• By End-User
  • Hospitals
  • Cardiac Surgery Centers
  • Ambulatory Surgical Centers
  • Other End-Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 45.47% of the annuloplasty rings market share in 2025, which made it the largest regional contributor. The United States accounts for most of that base because it combines high per-capita cardiac surgery activity with established reimbursement and a dense network of high-volume valve centers. Canada adds stable demand through its public system, although purchasing cycles can move more slowly. Premium device adoption is also supported by better sizing workflows, and a 2026 University of Freiburg study found that 3D assessment improved annuloplasty ring size prediction compared with conventional 2D measurements.

Europe remained the second-largest regional block in the annuloplasty rings market in 2025, supported by Germany, the United Kingdom, and France. Centralized procurement of CE-marked devices and consistently high procedure volumes help keep demand stable across the region. EU MDR timelines extend commercialization for newer platforms, but once approval is secured, rollout across multiple countries can still move efficiently. LivaNova presented Memo 3D ReChord data at AATS Week 2025 that highlighted improved surgical accuracy and a short learning curve, which reinforces Europe's role as a validation ground for newer ring designs.

Asia-Pacific is projected to expand at an 11.72% CAGR through 2031, making it the fastest-growing geography in the annuloplasty rings market. Growth in this region is being driven by aging populations and by continued expansion of advanced cardiac surgery infrastructure across China, India, Japan, and South Korea. Japan remains a premium market because hybrid operating room availability and robotic cardiac surgery capabilities are already well developed. South Korean tertiary centers are also piloting AI-assisted sizing tools for mitral repair planning, which points to stronger use of digital support in future procedural workflows. Middle East and Africa remain smaller in absolute size, but the 2025 Accra Declaration made clear that bulk procurement and more local consumable manufacturing are needed to improve the sustainability of cardiac surgery. South America is still emerging, with Brazil and Argentina anchoring most private-center structural heart activity and providing the main base for regional annuloplasty demand.

1. Abbott Laboratories
2. Affluent Medical
3. Artivion, Inc.
4. B. Braun
5. Beijing Balance Medical Technology Co., Ltd.
6. Boston Scientific
7. Braile Biomedica
8. Cardinal Health
9. Cook Group
10. Corcym S.r.l.
11. Edward Lifesciences
12. Genesee BioMedical, Inc.
13. Getinge
14. Jenavalve Technology
15. LivaNova
16. Medtronic
17. Meril Life Science
18. Micro Interventional Devices, Inc.
19. NeoChord, Inc.
20. Terumo
21. Valcare Medical Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Global Burden of Valvular Heart Disease
  • 4.2.2 Aging Cardiovascular Patient Pool Requiring Valve Repair
  • 4.2.3 Preference for Valve Repair Over Replacement in Clinical Guidelines
  • 4.2.4 Expanding Adoption of Minimally Invasive and Robotic Cardiac Surgery
  • 4.2.5 Premiumization Through Next-Generation Biocompatible Ring Designs
  • 4.2.6 Increased Use of Ring Sizing and Imaging Guidance to Improve Surgical Outcomes
• 4.3 Market Restraints
  • 4.3.1 High Procedure and Device Cost in Elective Valve Repair
  • 4.3.2 Limited Specialist Access in Low-Resource Cardiac Centers
  • 4.3.3 Stringent Regulatory and Clinical Evidence Requirements
  • 4.3.4 Long Procurement Cycles for Hospital Capital Committees
• 4.4 Supply/Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Saddle Shaped Annuloplasty Rings
  • 5.1.2 Flat Shaped Annuloplasty Rings
• 5.2 By Material
  • 5.2.1 Polyester Fabric-Covered Rings
  • 5.2.2 Titanium Core Rings
  • 5.2.3 Nitinol-Based Rings
  • 5.2.4 Other Materials
• 5.3 By Application
  • 5.3.1 Mitral Valve Repair
  • 5.3.2 Tricuspid Valve Repair
  • 5.3.3 Aortic Valve Repair
  • 5.3.4 Pulmonary Valve Repair
  • 5.3.5 Combined Valve Repair
• 5.4 By End-User
  • 5.4.1 Hospitals
  • 5.4.2 Cardiac Surgery Centers
  • 5.4.3 Ambulatory Surgical Centers
  • 5.4.4 Other End-Users
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 Affluent Medical
  • 6.3.3 Artivion, Inc.
  • 6.3.4 B. Braun Melsungen AG
  • 6.3.5 Beijing Balance Medical Technology Co., Ltd.
  • 6.3.6 Boston Scientific Corporation
  • 6.3.7 Braile Biomedica
  • 6.3.8 Cardinal Health, Inc.
  • 6.3.9 Cook Medical
  • 6.3.10 Corcym S.r.l.
  • 6.3.11 Edwards Lifesciences Corporation
  • 6.3.12 Genesee BioMedical, Inc.
  • 6.3.13 Getinge AB
  • 6.3.14 JenaValve Technology, Inc.
  • 6.3.15 LivaNova PLC
  • 6.3.16 Medtronic plc
  • 6.3.17 Meril Life Sciences Pvt. Ltd.
  • 6.3.18 Micro Interventional Devices, Inc.
  • 6.3.19 NeoChord, Inc.
  • 6.3.20 Terumo Corporation
  • 6.3.21 Valcare Medical Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment